* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.
Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...
It’s not known whether Repatha (evolocumab) is safe to receive while pregnant or breastfeeding. Certain factors may determine whether you can receive the drug during this time. If you may be or can ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results